(Q37784481)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Teresa Di Desidero

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Romano Danesi

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

6

Guido Bocci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

3

Lisa Derosa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Andrea Fontana

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

689-696

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11537480-000000000-00000

13 February 2020

exact match

0 references

cites work

Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11537480-000000000-00000

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

12 December 2020

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Management of hormone refractory prostate cancer

1 reference

12 December 2020

Treatment of prostate cancer in unfit senior adult patients

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

12 December 2020

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

1 reference

12 December 2020

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

12 December 2020

To widen the setting of cancer patients who could benefit from metronomic capecitabine

1 reference

12 December 2020

Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

1 reference

12 December 2020

Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

1 reference

12 December 2020

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

1 reference

12 December 2020

Oral metronomic cyclophosphamide in elderly with metastatic melanoma

1 reference

12 December 2020

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

12 December 2020

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer

1 reference

12 December 2020

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

1 reference

12 December 2020

Management of prostate cancer in the older man.

1 reference

12 December 2020

[A case of metronomic chemotherapy as an alternative cancer therapy for palliation].

1 reference

12 December 2020

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

1 reference

12 December 2020

Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

1 reference

12 December 2020

Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?

1 reference

12 December 2020

Innovations in the systemic therapy of prostate cancer

1 reference

12 December 2020

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

12 December 2020

Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma

1 reference

12 December 2020

Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?

1 reference

12 December 2020

10.2165/11537480-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20809660%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

1005247826

0 references

Fatcat ID

release_iqsaysdhvnfyjcwcxb6nhmlblq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iqsaysdhvnfyjcwcxb6nhmlblq

24 November 2022

mapped directly with Wikidata item

1 reference